Kim Hyun Jung, Oh Jae Sang, Park Sukh Que, Yoon Seok Mann, Ahn Hyeong Sik, Kim Bum Tae
Department of Public Health, Graduate School of Korea University, Seoul, Korea.
Department of Neurosurgery, Soonchunhyang University Cheonan Hospital, Soonchunhyang University College of Medicine, Cheonan, Korea.
J Korean Neurosurg Soc. 2020 Sep;63(5):539-549. doi: 10.3340/jkns.2019.0082. Epub 2019 Oct 30.
The efficacy of P2Y12 reaction unit (PRU) of VerifyNow still remains as a controversial issue in neurointervention. So we investigated the usefulness of PRU of VerifyNow to predict the peri-procedural thromboembolic events (TE) and hemorrhagic events (HE). And we evaluated the safety of modified dual antiplatelet therapy (DAPT) or triple antiplatelet therapy (TAPT) for clopidogrel hyporesponders. We searched MEDLINE, EMBASE, the Cochrane Central Register of Controlled Trials, Web of Science and Scopus on August 19 2018. Data was collected the 1) incidence of TE between clopidogrel responder and clopidogrel hypo-responder, 2) incidence of HE between clopidogrel hyper-responder and clopidogrel responder and hypo-responder, and 3) incidence of TE and HE between modified DAPT or TAPT and standard DAPT in clopidogrel hypo-responder. High cut-off value of PRU was defined as PRU >40% or <220. Fifteen studies were enrolled. Clopidogrel responder showed lower incidence of TE than hypo-responder (risk ratio [RR], 0.32; 95% confidence interval [CI], 0.17-0.61; p<0.001). With the high cut-off value of PRU, clopidogrel responder showed more lower incidence of TE than hypo-responder (RR, 0.11; 95% CI, 0.02-0.45; p=0.002). The incidence of periprocedural HE have higher on clopidogrel hyper-responder than clopidogrel responder and hypo-responder (RR, 4.26; 95% CI, 1.10-16.44; p=0.04; I2=66%). The incidence of periprocedural TE after changing regimen of DAPT for clopidogrel hypo-responder have a tendency to reduce, but there was no significant difference between modified DAPT or TAPT group and standard DAPT group (p>0.05). The incidence of periprocedural HE after changing regimen of DAPT for clopidogrel hypo-responder was no significant difference between modified DAPT or TAPT group and standard DAPT group (p>0.05). PRU is a useful tool as a predictor of peri-procedural TE or HE on neurointervention. PRU has a threshold effect of cut-off value to predict the peri-procedural TE. Modified DAPT or TAPT to prevent TE in clopidogrel hypo-responders could not reduce the incidence of TE. We should investigate the further research about modification of regiment on neurointervention.
在神经介入治疗中,VerifyNow的P2Y12反应单元(PRU)的疗效仍然是一个有争议的问题。因此,我们研究了VerifyNow的PRU预测围手术期血栓栓塞事件(TE)和出血事件(HE)的实用性。并且我们评估了氯吡格雷低反应者采用改良双联抗血小板治疗(DAPT)或三联抗血小板治疗(TAPT)的安全性。我们于2018年8月19日检索了MEDLINE、EMBASE、Cochrane对照试验中央注册库、科学网和Scopus。收集了以下数据:1)氯吡格雷反应者与氯吡格雷低反应者之间的TE发生率;2)氯吡格雷高反应者与氯吡格雷反应者及低反应者之间的HE发生率;3)氯吡格雷低反应者中改良DAPT或TAPT与标准DAPT之间的TE和HE发生率。PRU的高截断值定义为PRU>40%或<220。纳入了15项研究。氯吡格雷反应者的TE发生率低于低反应者(风险比[RR],0.32;95%置信区间[CI],0.17 - 0.61;p<0.001)。采用PRU的高截断值时,氯吡格雷反应者的TE发生率比低反应者更低(RR,0.11;95%CI,0.02 - 0.45;p = 0.002)。围手术期HE的发生率在氯吡格雷高反应者中高于氯吡格雷反应者和低反应者(RR,4.26;95%CI,1.10 - 16.44;p = 0.04;I² = 66%)。氯吡格雷低反应者更换DAPT方案后围手术期TE的发生率有降低趋势,但改良DAPT或TAPT组与标准DAPT组之间无显著差异(p>0.05)。氯吡格雷低反应者更换DAPT方案后围手术期HE的发生率在改良DAPT或TAPT组与标准DAPT组之间无显著差异(p>0.05)。PRU是神经介入治疗中围手术期TE或HE的有用预测工具。PRU在预测围手术期TE时有截断值的阈值效应。改良DAPT或TAPT预防氯吡格雷低反应者的TE并不能降低TE的发生率。我们应该对神经介入治疗方案的改良进行进一步研究。